Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
433.5 GBX | +1.40% | +1.05% | +3.71% |
May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
Apr. 25 | SThree plc Approves Final Dividend | CI |
Sales 2024 * | 1.65B 2.07B | Sales 2025 * | 1.76B 2.21B | Capitalization | 576M 724M |
---|---|---|---|---|---|
Net income 2024 * | 51M 64.05M | Net income 2025 * | 60M 75.35M | EV / Sales 2024 * | 0.31 x |
Net cash position 2024 * | 71.54M 89.84M | Net cash position 2025 * | 78.93M 99.13M | EV / Sales 2025 * | 0.28 x |
P/E ratio 2024 * |
11.3
x | P/E ratio 2025 * |
9.69
x | Employees | 2,654 |
Yield 2024 * |
3.71% | Yield 2025 * |
4.05% | Free-Float | 88.73% |
Latest transcript on SThree plc
1 day | +1.40% | ||
1 week | +1.05% | ||
Current month | +1.64% | ||
1 month | +0.35% | ||
3 months | +1.17% | ||
6 months | +12.02% | ||
Current year | +3.71% |
Managers | Title | Age | Since |
---|---|---|---|
Timo Lehne
CEO | Chief Executive Officer | - | 21-12-31 |
Andrew Beach
DFI | Director of Finance/CFO | 49 | 21-07-04 |
Nick Folkes
COO | Chief Operating Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Elaine O'Donnell
BRD | Director/Board Member | 53 | 22-09-30 |
Director/Board Member | - | 22-11-30 | |
James Bilefield
CHM | Chairman | 55 | 17-09-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 433.5 | +1.40% | 164,303 |
24-05-10 | 427.5 | -1.38% | 187,581 |
24-05-09 | 433.5 | -0.12% | 172,819 |
24-05-08 | 434 | -0.34% | 142,936 |
Delayed Quote London S.E., May 13, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+3.71% | 711M | |
-11.90% | 9.38B | |
-19.03% | 7.3B | |
-13.93% | 6.37B | |
-1.99% | 3.66B | |
-9.05% | 3.25B | |
+12.38% | 1.71B | |
-2.71% | 1.49B | |
+9.77% | 1.49B | |
-4.65% | 1.2B |
- Stock Market
- Equities
- STHR Stock